{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:08:20Z","timestamp":1789715300507,"version":"4.0.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":2567,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1038\/modpathol.2015.121","type":"journal-article","created":{"date-parts":[[2015,10,23]],"date-time":"2015-10-23T07:43:27Z","timestamp":1445586207000},"page":"14-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"title":["The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma"],"prefix":"10.1016","volume":"29","author":[{"given":"Aatur D","family":"Singhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa M","family":"Krasinskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroon A","family":"Choudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F","family":"Pingpank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert J","family":"Zeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Luvison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Fuhrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Bahary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja R","family":"Seethala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Dacic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/modpathol.2015.121_bib1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11864-008-0072-2","article-title":"Peritoneal mesothelioma","volume":"9","author":"Hesdorffer","year":"2008","journal-title":"Curr Treat Options Oncol"},{"key":"10.1038\/modpathol.2015.121_bib2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/aje\/kwh025","article-title":"Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003","volume":"159","author":"Price","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1038\/modpathol.2015.121_bib3","first-page":"32","article-title":"Peritoneal mesothelioma: a review","volume":"9","author":"Bridda","year":"2007","journal-title":"MedGenMed"},{"key":"10.1038\/modpathol.2015.121_bib4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/030089160308900307","article-title":"Clinical presentation of peritoneal mesothelioma","volume":"89","author":"Acherman","year":"2003","journal-title":"Tumori"},{"key":"10.1038\/modpathol.2015.121_bib5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1056\/NEJM198007243030407","article-title":"Current concepts: malignant mesothelioma","volume":"303","author":"Antman","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2015.121_bib6","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0140-6736(85)90526-4","article-title":"Early peritoneal mesothelioma: a treatable malignancy","volume":"2","author":"Antman","year":"1985","journal-title":"Lancet"},{"key":"10.1038\/modpathol.2015.121_bib7","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s004230050246","article-title":"Management of peritoneal-surface malignancy: the surgeon's role","volume":"384","author":"Sugarbaker","year":"1999","journal-title":"Langenbecks Arch Surg"},{"key":"10.1038\/modpathol.2015.121_bib8","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/annonc\/mdl428","article-title":"A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma","volume":"18","author":"Yan","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1038\/modpathol.2015.121_bib9","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.surg.2013.01.001","article-title":"Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma","volume":"153","author":"Alexander","year":"2013","journal-title":"Surgery"},{"key":"10.1038\/modpathol.2015.121_bib10","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1200\/JCO.2003.04.150","article-title":"Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy","volume":"21","author":"Feldman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2015.121_bib11","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1245\/s10434-013-3358-y","article-title":"Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis","volume":"21","author":"Magge","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1038\/modpathol.2015.121_bib12","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1177\/000313480106701019","article-title":"Prospective trial for the treatment of malignant peritoneal mesothelioma","volume":"67","author":"Loggie","year":"2001","journal-title":"Am Surg"},{"key":"10.1038\/modpathol.2015.121_bib13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1245\/ASO.2006.03.045","article-title":"Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion","volume":"13","author":"Deraco","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1038\/modpathol.2015.121_bib14","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2015.121_bib15","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1055-3207(03)00045-0","article-title":"A review of peritoneal mesothelioma at the Washington Cancer Institute","volume":"12","author":"Sugarbaker","year":"2003","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1038\/modpathol.2015.121_bib16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1038\/modpathol.2015.121_bib17","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"10.1038\/modpathol.2015.121_bib18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1038\/modpathol.2015.121_bib19","first-page":"5547","article-title":"p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma","volume":"54","author":"Cheng","year":"1994","journal-title":"Cancer Res"},{"key":"10.1038\/modpathol.2015.121_bib20","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","article-title":"High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas","volume":"92","author":"Bianchi","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/modpathol.2015.121_bib21","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2015.121_bib22","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00428-008-0689-3","article-title":"Prognostic significance of p16\/cdkn2a loss in pleural malignant mesotheliomas","volume":"453","author":"Dacic","year":"2008","journal-title":"Virchows Arch"},{"key":"10.1038\/modpathol.2015.121_bib23","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/modpathol.2008.45","article-title":"Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas","volume":"21","author":"Chiosea","year":"2008","journal-title":"Mod Pathol"},{"key":"10.1038\/modpathol.2015.121_bib24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.lungcan.2008.02.013","article-title":"Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma","volume":"62","author":"Kobayashi","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1038\/modpathol.2015.121_bib25","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","article-title":"Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction","volume":"66","author":"Lopez-Rios","year":"2006","journal-title":"Cancer Res"},{"key":"10.1038\/modpathol.2015.121_bib26","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lungcan.2008.08.014","article-title":"Functional inactivation of NF2\/merlin in human mesothelioma","volume":"64","author":"Thurneysen","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1038\/modpathol.2015.121_bib27","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1128\/MCB.25.6.2384-2394.2005","article-title":"The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression","volume":"25","author":"Xiao","year":"2005","journal-title":"Mol Cell Biol"},{"key":"10.1038\/modpathol.2015.121_bib28","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1038\/sj.onc.1206593","article-title":"Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours","volume":"22","author":"Fleury-Feith","year":"2003","journal-title":"Oncogene"},{"key":"10.1038\/modpathol.2015.121_bib29","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/PAS.0000000000000394","article-title":"BAP1 Immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations","volume":"39","author":"Sheffield","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/modpathol.2015.121_bib30","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/PAT.0000000000000250","article-title":"Loss of expression of BAP1 predicts longer survival in mesothelioma","volume":"47","author":"Farzin","year":"2015","journal-title":"Pathology"},{"key":"10.1038\/modpathol.2015.121_bib31","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1038\/modpathol.2015.121_bib32","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/modpathol.2009.186","article-title":"CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival","volume":"23","author":"Krasinskas","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1038\/modpathol.2015.121_bib33","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat Res"},{"key":"10.1038\/modpathol.2015.121_bib34","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.3747\/co.v18i2.663","article-title":"A new standard of care for the management of peritoneal surface malignancy","volume":"18","author":"Mohamed","year":"2011","journal-title":"Curr Oncol"},{"key":"10.1038\/modpathol.2015.121_bib35","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/jcp.2010.076794","article-title":"FISH assay development for the detection of p16\/CDKN2A deletion in malignant pleural mesothelioma","volume":"63","author":"Chung","year":"2010","journal-title":"J Clin Pathol"},{"key":"10.1038\/modpathol.2015.121_bib36","doi-asserted-by":"crossref","first-page":"632","DOI":"10.5858\/arpa.2012-0108-OA","article-title":"p16 Deletion in sarcomatoid tumors of the lung and pleura","volume":"137","author":"Tochigi","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"10.1038\/modpathol.2015.121_bib37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1309\/AJCPT94JVWIHBKRD","article-title":"Diagnostic usefulness of p16\/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis","volume":"139","author":"Wu","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/modpathol.2015.121_bib38","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Tsao","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2015.121_bib39","first-page":"145","article-title":"Asbestos-related mesothelioma: factors discriminating between pleural and peritoneal sites","volume":"40","author":"Browne","year":"1983","journal-title":"Br J Ind Med"},{"key":"10.1038\/modpathol.2015.121_bib40","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/sj.onc.1209809","article-title":"Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors","volume":"26","author":"Borczuk","year":"2007","journal-title":"Oncogene"},{"key":"10.1038\/modpathol.2015.121_bib41","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/modpathol.3800067","article-title":"Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers","volume":"17","author":"Trupiano","year":"2004","journal-title":"Mod Pathol"},{"key":"10.1038\/modpathol.2015.121_bib42","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ccr.2008.01.030","article-title":"A conditional mouse model for malignant mesothelioma","volume":"13","author":"Jongsma","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1038\/modpathol.2015.121_bib43","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/jso.21055","article-title":"Consensus statement on peritoneal mesothelioma","volume":"98","author":"Deraco","year":"2008","journal-title":"J Surg Oncol"},{"key":"10.1038\/modpathol.2015.121_bib44","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/cncr.25640","article-title":"A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*","volume":"117","author":"Yan","year":"2011","journal-title":"Cancer"},{"key":"10.1038\/modpathol.2015.121_bib45","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1097\/JTO.0b013e31829e7ef9","article-title":"Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations","volume":"8","author":"Zauderer","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1038\/modpathol.2015.121_bib46","first-page":"484A","article-title":"BAP1 loss portends improved prognosis in malignant pleural mesothelioma due to frequent association with epithelioid morphology","volume":"28","author":"McGregor","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1038\/modpathol.2015.121_bib47","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4240\/wjgs.v1.i1.38","article-title":"Malignant peritoneal mesothelioma","volume":"1","author":"Munkholm-Larsen","year":"2009","journal-title":"World J Gastrointest Surg"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/modpathol2015121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol2015121","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222013138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222013138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol2015121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:48:06Z","timestamp":1760230086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222013138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0893395222013138"],"URL":"https:\/\/doi.org\/10.1038\/modpathol.2015.121","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/modpathol.2015.121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}